Previous studies reported a lower SLC5A5 expression in cases harboring BRAFV600E, and there is experimental evidence showing that BRAFV600E can impair SLC5A5 expression (1, 19, 27, 39), nevertheless the impact of other relevant mutations found in thyroid tumors on SLC5A5 expression remained unknown. The gene discussed is SLC5A5; the disease is thyroid tumor.